Skip to content

Royalty Pharma

US · RPRX #759 by market cap Listed 2020
68.45 +0.73 +1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 17.62 Million in Common Stocks
    Market Newswire · 2026/11/17
  • Rating change
    UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/8/11
  • Rating change
    TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/9/8
  • Rating change
    J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
    Market Newswire · 2026/8/11
  • Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 10.18 Million in Common Stocks
    Market Newswire · 2026/11/18
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $67
    Market Newswire · 2026/10/7
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $63
    Market Newswire · 2026/10/9
  • Rating change
    J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $74
    Market Newswire · 2026/11/5
  • Rating change
    UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/9/8
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $75
    Market Newswire · 2026/11/5
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/8/6
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/12
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63
    Market Newswire · 2026/9/24
  • Royalty Pharma(RPRX.US) Officer Sells US$6.81 Million in Common Stock
    Market Newswire · 2026/11/19
  • TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $80
    Market Newswire · 2026/11/18
  • Royalty Pharma(RPRX.US) Officer Sells US$17.69 Million in Common Stock
    Market Newswire · 2026/11/19
  • Rating change
    Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/8/7
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/6
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $78
    Market Newswire · 2026/11/5
  • Rating change
    TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/7/13
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/5/7
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating
    Market Newswire · 2026/7/10
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/7/16
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
    Market Newswire · 2026/5/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.

Royalty Pharma discussion 0 comments

Add a comment